Crizanlizumab for Sickle Cell Disease
(SPARKLE Trial)
Trial Summary
What is the purpose of this trial?
A phase III, multi-center, randomized, placebo-controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult Sickle Cell Disease patients with frequent vaso-occlusive crises.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, if you are on hydroxyurea/hydroxycarbamide or an erythropoietin stimulating agent, you must have been on a stable dose for at least 3 months and plan to continue it during the study.
What data supports the effectiveness of the drug crizanlizumab for sickle cell disease?
Is crizanlizumab safe for humans?
What makes the drug Crizanlizumab unique for treating Sickle Cell Disease?
Crizanlizumab is unique because it targets P-selectin, a protein that plays a key role in the inflammation and blockage of blood vessels in Sickle Cell Disease, helping to reduce pain crises. This mechanism is different from other treatments that primarily focus on managing symptoms or increasing fetal hemoglobin levels.7891011
Eligibility Criteria
This trial is for adolescents and adults aged 12 years and older with confirmed Sickle Cell Disease (SCD). They must have experienced 4 to 12 vaso-occlusive crises (VOCs) in the past year. If they're on hydroxyurea/hydroxycarbamide, it should be a stable dose for at least 3 months before the study.Inclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Crizanlizumab 5 mg/kg or placebo, with or without hydroxyurea/hydroxycarbamide therapy, for the management of vaso-occlusive crises
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term follow-up
Participants are monitored for long-term safety and efficacy outcomes, including adverse events and immunogenicity
Treatment Details
Interventions
- Crizanlizumab (Monoclonal Antibodies)
Crizanlizumab is already approved in United States for the following indications:
- Prevention of recurrent vaso-occlusive crises in sickle cell disease patients aged 16 years and older